219 related articles for article (PubMed ID: 17226906)
21. Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Papi C; Camarri E
Ital J Gastroenterol; 1992; 24(9 Suppl 2):19-22. PubMed ID: 1336684
[TBL] [Abstract][Full Text] [Related]
22. Management of diverticular disease: is there room for rifaximin?
Papi C; Koch M; Capurso L
Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
[TBL] [Abstract][Full Text] [Related]
23. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
[TBL] [Abstract][Full Text] [Related]
24. Diverticular Disease and Rifaximin: An Evidence-Based Review.
Piccin A; Gulotta M; di Bella S; Martingano P; Crocè LS; Giuffrè M
Antibiotics (Basel); 2023 Feb; 12(3):. PubMed ID: 36978310
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
Tursi A; Brandimarte G; Daffinà R
Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
[TBL] [Abstract][Full Text] [Related]
26. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103
[TBL] [Abstract][Full Text] [Related]
27. Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: a retrospective study.
Pietrzak AM; Dziki A; Banasiewicz T; Reguła J
Prz Gastroenterol; 2019; 14(1):69-78. PubMed ID: 30944680
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of alpha-normiks (rifaximin) efficacy in the treatment of patients with diverticular disease associated with medium and severe intestinal dysbacteriosis].
Lutkov IV
Eksp Klin Gastroenterol; 2009; (2):99-103. PubMed ID: 19552027
[TBL] [Abstract][Full Text] [Related]
29. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease.
Lahner E; Esposito G; Zullo A; Hassan C; Cannaviello C; Paolo MC; Pallotta L; Garbagna N; Grossi E; Annibale B
World J Gastroenterol; 2012 Nov; 18(41):5918-24. PubMed ID: 23139608
[TBL] [Abstract][Full Text] [Related]
30. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
Tursi A; Papa A; Danese S
Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
[TBL] [Abstract][Full Text] [Related]
31. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.
Dupont HL; Jiang ZD; Belkind-Gerson J; Okhuysen PC; Ericsson CD; Ke S; Huang DB; Dupont MW; Adachi JA; De La Cabada FJ; Taylor DN; Jaini S; Martinez Sandoval F
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):451-6. PubMed ID: 17382603
[TBL] [Abstract][Full Text] [Related]
32. Colonic diverticular disease.
Tursi A; Scarpignato C; Strate LL; Lanas A; Kruis W; Lahat A; Danese S
Nat Rev Dis Primers; 2020 Mar; 6(1):20. PubMed ID: 32218442
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon.
Di Mario F; Miraglia C; Cambiè G; Violi A; Nouvenne A; Franceschi M; Brandimarte G; Elisei W; Picchio M; Tursi A
J Investig Med; 2019 Apr; 67(4):767-770. PubMed ID: 30593541
[TBL] [Abstract][Full Text] [Related]
34. Management of colonic diverticular disease.
Frieri G; Pimpo MT; Scarpignato C
Digestion; 2006; 73 Suppl 1():58-66. PubMed ID: 16498253
[TBL] [Abstract][Full Text] [Related]
35. Medical treatment of uncomplicated diverticular disease of the colon: any progress?
Guslandi M
Minerva Gastroenterol Dietol; 2010 Sep; 56(3):367-70. PubMed ID: 21037552
[TBL] [Abstract][Full Text] [Related]
36. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review.
Carabotti M; Annibale B; Severi C; Lahner E
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28230737
[TBL] [Abstract][Full Text] [Related]
37. Rationale and evidences for treatment of symptomatic uncomplicated diverticular disease.
Cuomo R; Cargiolli M; Andreozzi P; Zito FP; Sarnelli G
Minerva Gastroenterol Dietol; 2017 Jun; 63(2):130-142. PubMed ID: 27973463
[TBL] [Abstract][Full Text] [Related]
38. General practitioners' management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic.
De Bastiani R; Sanna G; Bertolusso L; Casella G; De Polo M; Zamparella M; Cottone C; Tosetti C; Mancuso M; Pirrotta E; Lanzarotto L; Napoli L; De Bastiani M; Disclafani G; Gambaro P; Scoglio R; Belvedere A; Fasulo S; D'Urso M; Benedetto E; Baldi E; Marchesan F; Abagnale G; Turnava L; Salomè E; Ingravalle F; Tursi A
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):423-430. PubMed ID: 33506932
[TBL] [Abstract][Full Text] [Related]
39. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial.
Ramas M; Donday MG; McNicholl AG; Gisbert JP
Gastroenterol Hepatol; 2017 Dec; 40(10):658-662. PubMed ID: 28780968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
